Swiss Competition Commission investigates pharma suppliersChristian Fernsby ▼ | February 24, 2020
The Swiss Competition Commission (COMCO) has opened an investigation against several manufacturers and distributors of active pharmaceutical ingredients.
Business in Switzerland Scopolamine Butylbromide
Topics: Swiss competition pharma
COMCO suspects that manufacturers and distributers of the active pharmaceutical ingredient Scopolamine Butylbromide have concluded unlawful price and market sharing agreements.
There are reasonable grounds to suspect that the undertakings have kept the prices of this pharmaceutical ingredient high and that they have allocated markets.
The investigation shall examine whether there are indeed unlawful restrictions of competition.
This pharmaceutical ingredient is used for the production of drugs against spasmodic stomach pains, renal colic and bladder spasms.
The manufacturers and distributors of Scopolamine Butylbromide resell this pharmaceutical ingredient to drug manufacturers. ■